Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirofiban Versus Intravenous Aspirin in Acute Ischemic Stroke With Tandem Lesions
NCT05225961Phase 4Completed
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Mar 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tirofiban in ischemic stroke (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoints: Carotid Reocclusion at 24 hours, Platelet aggregation phenomena at 24 hours and 1 more. Started Mar 2026; status: completed.
02
Drugs
tirofiban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05225961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05225961.